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Bivalirudin Versus Eptifibatide: Results From PROTECT TIMI-30
The Thrombolysis In Myocardial Infarction (TIMI) Study Group Investigatorspresent two papers in this issue with results from the PROTECT–TIMI-30 trial,
which was a three-arm trial comparing bivalirudin versus eptifibatide with either
unfractionated heparin or enoxaparin in patients with acute coronary syndromes
undergoing percutaneous coronary intervention (PCI). The primary end point of
post-PCI coronary flow reserve favored bivalirudin. This end point is measured by the
corrected TIMI frame count comparing post-PCI angiographic images before and after
the administration of intracoronary adenosine. A secondary, but similar end point of
myocardial perfusion grade favored eptifibatide. Bleeding complications were higher
with eptifibatide regimens. The second study looked at bleeding complications among
patients receiving eptifibatide. Higher rates of bleeding complications were associated
with increased age and with a lack of renal dosing adjustment for those patients with
creatinine clearance rates50 ml/min. An editorial by Bittl discusses the results of this
trial and its impact on anticoagulation strategies for those patients undergoing PCI,
especially the apparently conflicting results from the primary and secondary end points.
See pages 2364, 2374, and 2380.
Interventional Cardiology
Carotid Stenting: New Distal Protection and Serial IVUS Studies
Two papers and an accompanying editorial discuss new research on carotid stent-ing techniques. Safian and colleagues report on their experience with the SPIDER
protection system in a registry of more than 400 patients. In these high-risk patients,
the overall complication rate was 6.2%, which is comparable to that in other published
series. In a multivariate analysis, filter deployment longer than 20 minutes nearly
doubled the risk of death or stroke. In another study, Clark and colleagues performed
serial IVUS measurements on patients undergoing carotid stenting with self-expanding
stents. At 6 months, the cross-sectional area of the stent was 49% greater, however,
neointimal hyperplasia increased by 37%; the final cross-sectional area 6 months after
stenting was similar to that immediately after stenting because of these competing
processes. An editorial by Yadav discusses the implications and deficiencies of these
trials and raises questions that need to be answered by further studies. See pages




Virtual Histology From IVUS
Recently, a technology that uses intravascular ultrasound (IVUS) radiofrequencybackscatter analysis has been developed and termed Virtual Histology (VH) for
its ability to delineate plaque components. It provides real-time images that color code
areas of the lesion according to its likely composition. Nasu and colleagues report on
the first comparison of this technology with histopathology samples taken from
directional atherectomy. The IVUS-VH was able to accurately characterize areas of the
plaque as either fibrous, fibro-fatty, necrotic core, or dense calcium. This study
demonstrates that IVUS-VH has good correlation with tissue histopathology and may
be useful for identifying plaque characteristics that are more likely to rupture.
See page 2405. See figure.
(continued) A-47Atherosclerosis
Carotid IMT Correlates With Early Myocardial Dysfunction
The Multi-Ethnic Study of Atherosclerosis (MESA) study is a large cross-sectional study examining the links between cardiac risk factors and early
atherosclerosis. In this report, Fernandes and colleagues correlated carotid
intima-media thickness (IMT) with cardiac magnetic resonance imaging stud-
ies. Subjects with thickened carotid IMT were found to have reduced systolic
and diastolic strain rates suggesting early myocardial dysfunction. More studies
are needed to know if the reduced myocardial function is related to atheroscle-
rosis and transient ischemia or to alterations in the pulse wave propagation
reflected back into the left ventricle from stiffer systemic arteries, but the
association between early atherosclerosis and myocardial dysfunction appears
strong. See page 2420.
Heart Failure
Discontinuing Beta-Blockers for CHF May Be Dangerous
Although beta-blocker (BB) therapy has demonstrated strong gains inmortality for patients with systolic dysfunction, there remains debate
about the dosing of these medications when patients become decompensated.
Butler and colleagues analyzed the effects of continuing, lowering, or discon-
tinuing BB therapy in over 400 patients hospitalized with heart failure (HF).
Approximately one-fifth of patients had their BB medication either discontin-
ued or reduced by 50%. These patients appear to have been sicker, but after
statistical adjustment, those who had their dose lowered or discontinued were
nearly 4 times more likely to be rehospitalized or die during the subsequent 6
months. The authors conclude that BB therapy prior to and during hospital-
ization for HF is associated with improved outcomes in this non-randomized
study. See page 2462.
Page 2480
Heart Failure
Implant ICDs Quickly for Non-Ischemic Cardiomyopathies
Although implantable cardioverter-defibrillators (ICDs) clearly improvemortality in patients with both ischemic and non-ischemic cardiomyop-
athies, there remains substantial uncertainty regarding the optimal timing for
ICD implantation. Kadish and colleagues reanalyzed data from the
DEFINITE study to determine if there was evidence that waiting for a few
months after diagnosis of a non-ischemic cardiomyopathy prior to ICD
implantation was safe. Subjects, who had and ejection fraction of 35% and
no identifiable reversible etiology for their cardiomyopathy were categorized as
either recently or remotely diagnosed. Those who had been diagnosed within 3
months prior to implantation had the greatest benefit from ICD therapy, with
little benefit in those who had been remotely diagnosed. This study suggests
that there is no benefit, and the possibility of harm, associated with a strategy
of waiting 6 months after diagnosis to implant an ICD in patients with a
non-ischemic cardiomyopathy. See page 2477. See figure.
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Heart Rhythm Disorders
Biatrial Procedure Superior to PV Isolation for Persistent AF
Pulmonary vein isolation has high rates of success in preventing atrial fibrillation(AF) recurrences in patients with paroxysmal episodes, but it is less efficacious in
patients with permanent AF. Calò and colleagues extrapolated from other lines of
evidence that linear ablations in the right atrium would increase the efficacy of left atrial
ablation procedures. Eighty patients were randomized to either standard left atrial
ablation with pulmonary vein isolation, or this procedure plus several ablation lines in
the right atrium. Ablating the right atrium appears safe, with no reported complications
and only modest increases in procedure, fluoroscopy, and ablation times. After approx-
imately 1 year of follow-up, AF recurred in 39% of patients in the left atrial ablation
group versus only 15% of patients in the biatrial ablation group. This study reports that
adding ablation lines in the right atrium can substantially increase the success rates for
patients with permanent AF. See page 2504. See figure.
